Xtandi (Enzalutamide) Phase 3 Clinically Significantly Prolongs Survival--2/2

Cov txiaj ntsig tau tshaj tawm ntawm lub rooj sib tham ESMO tau qhia tias piv nrog cov placebo+ADT pawg tswj hwm, qhov kev pheej hmoo ntawm kev tuag hauv Xtandi+ADT pawg tau txo qis los ntawm 34% (HR=0.66 [95% CI: 0.53-0.81]; p< 0.0001).="" qhov="" nruab="" nrab="" os="" sawv="" cev="" rau="" lub="" sijhawm="" los="" ntawm="" randomization="" mus="" rau="" kev="" tuag="" vim="" yog="" ib="" qho="" laj="" thawj,="" thiab="" qhov="" nruab="" nrab="" os="" tsis="" tau="" mus="" txog="" hauv="" ob="" pawg="" kho="" mob.="" kev="" nyab="" xeeb="" ntawm="" 2="" pawg="" tau="" ua="" raws="" li="" qhov="" kev="" ntsuam="" xyuas="" ua="">

Hauv kev tshuaj xyuas ua ntej, kev nyab xeeb ntawm Xtandi yog ua raws li kev nyab xeeb ntawm CRPC kev sim tshuaj yav dhau los. Cov xwm txheej tsis zoo (AE) ntawm qib 3 lossis siab dua (txhais tias yog mob hnyav / xiam oob khab lossis ua rau muaj sia nyob) raug kho nrog Xtandi+ADT kev tswj hwm Tus naj npawb ntawm cov neeg mob zoo ib yam li cov neeg mob tau txais cov placebo+ ADT kev tswj hwm (24.3% vs 25.6%).

enzalutamidechemical qauv

Thoob plaws ntiaj teb, mob qog noj ntshav prostate yog qhov thib ob ua rau kev tuag ntawm cov txiv neej tom qab mob ntsws cancer. Mob qog noj ntshav prostate feem ntau tshwm sim hauv cov neeg laus thiab feem ntau tshwm sim los ntawm kev noj ntau dhau ntawm cov txiv neej cov tshuaj hormones (xws li testosterone, uas yog androgen). Kev kho mob raws li kev kho mob yog los txo cov theem ntawm androgens hauv lub cev, uas tuaj yeem raug castrated los ntawm kev phais thiab/los yog androgen deprivation Therapy (ADT) tiav.

Metastatic prostate cancer yog hais txog cov qog nqaij hlav cancer uas tau kis mus rau lwm qhov ntawm lub cev (xws li cov pob txha, qog nqaij hlav, zais zis, thiab qhov quav) uas tsis yog prostate. Yog tias tus neeg mob tseem teb rau cov txheej txheem phais lossis tshuaj kom txo qis testosterone theem ntawm lub sijhawm no, nws raug suav tias yog Hormone (los yog castration) rhiab heev. Rau cov txiv neej cov neeg mob nrog mHSPC uas tau pib ADT, lub sijhawm muaj sia nyob nruab nrab yog li 3-4 xyoos.

Xtandi (enzalutamide) yog ib qho androgen receptor signaling inhibitor. Nws yog noj ib hnub ib zaug. Cov tshuaj ncaj qha rau lub hom phiaj ntawm androgen receptor (AR) thiab ua lub luag haujlwm hauv peb kauj ruam ntawm AR signaling pathway. : (1) Inhibition of androgen binding-androgen binding induces conformational change to trigger receptor activation; (2) Tiv thaiv nuclear translocation-AR translocation rau lub nucleus yog ib kauj ruam tseem ceeb hauv AR-mediated gene regulation; (3) Tsis muaj zog DNA khi-Kev sib xyaw ntawm AR thiab DNA yog qhov tseem ceeb rau kev tswj cov noob caj noob ces.

Xtandi tau tsim tawm hauv xyoo 2012 thiab yog cov khoom lag luam loj hauv kev kho mob qog noj ntshav prostate. Cov tshuaj tau pom zoo rau ntau yam kev kho mob, uas txawv ntawm lub teb chaws mus rau lub teb chaws, xws li: metastatic castration-resistant prostate cancer (mCRPC), non-Metastatic castration-resistant prostate cancer (nmCRPC), metastatic castration-sensitive prostate cancer (mCSPC) . Nws yog ib qho tsim nyog hais tias Xtandi yog thawj cov khoom pom zoo rau kev kho mob ntawm peb hom mob qog nqaij hlav prostate (nmCRPC, mCRPC, mCSPC).